Biotech Co. Suspends $150M IPO, Citing Market Jitters
Braeburn Pharmaceuticals Inc., a New Jersey biotech that just launched an estimated $150 million initial public offering to help fund a drug treating opioid addiction, suspended plans Thursday, citing current market...To view the full article, register now.
Already a subscriber? Click here to view full article